129 related articles for article (PubMed ID: 31594764)
1. Moxetumomab pasudotox for hairy cell leukemia: preclinical development to FDA approval.
Lin AY; Dinner SN
Blood Adv; 2019 Oct; 3(19):2905-2910. PubMed ID: 31594764
[TBL] [Abstract][Full Text] [Related]
2. Immunoconjugates in the management of hairy cell leukemia.
Kreitman RJ; Pastan I
Best Pract Res Clin Haematol; 2015 Dec; 28(4):236-45. PubMed ID: 26614902
[TBL] [Abstract][Full Text] [Related]
3. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.
Kreitman RJ; Pastan I
Clin Cancer Res; 2011 Oct; 17(20):6398-405. PubMed ID: 22003067
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.
Kreitman RJ; Tallman MS; Robak T; Coutre S; Wilson WH; Stetler-Stevenson M; Fitzgerald DJ; Lechleider R; Pastan I
J Clin Oncol; 2012 May; 30(15):1822-8. PubMed ID: 22355053
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.
Wayne AS; Shah NN; Bhojwani D; Silverman LB; Whitlock JA; Stetler-Stevenson M; Sun W; Liang M; Yang J; Kreitman RJ; Lanasa MC; Pastan I
Blood; 2017 Oct; 130(14):1620-1627. PubMed ID: 28983018
[TBL] [Abstract][Full Text] [Related]
6. Immunoconjugates and new molecular targets in hairy cell leukemia.
Kreitman RJ
Hematology Am Soc Hematol Educ Program; 2012; 2012():660-6. PubMed ID: 23233649
[TBL] [Abstract][Full Text] [Related]
7. Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome.
Arons E; Adams S; Venzon DJ; Pastan I; Kreitman RJ
Br J Haematol; 2014 Sep; 166(5):729-38. PubMed ID: 24931452
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.
Kreitman RJ; Stetler-Stevenson M; Margulies I; Noel P; Fitzgerald DJ; Wilson WH; Pastan I
J Clin Oncol; 2009 Jun; 27(18):2983-90. PubMed ID: 19414673
[TBL] [Abstract][Full Text] [Related]
9. How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors.
Falini B; De Carolis L; Tiacci E
Blood; 2022 Apr; 139(15):2294-2305. PubMed ID: 35143639
[TBL] [Abstract][Full Text] [Related]
10. Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy.
Arons E; Sorbara L; Raffeld M; Stetler-Stevenson M; Steinberg SM; Liewehr DJ; Pastan I; Kreitman RJ
Cancer Immunol Immunother; 2006 Sep; 55(9):1100-10. PubMed ID: 16311729
[TBL] [Abstract][Full Text] [Related]
11. Interactions Between
Bokori-Brown M; Metz J; Petrov PG; Mussai F; De Santo C; Smart NJ; Saunders S; Knight B; Pastan I; Titball RW; Winlove CP
Front Oncol; 2018; 8():553. PubMed ID: 30538953
[TBL] [Abstract][Full Text] [Related]
12. Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.
Kreitman RJ; Dearden C; Zinzani PL; Delgado J; Robak T; le Coutre PD; Gjertsen BT; Troussard X; Roboz GJ; Karlin L; Gladstone DE; Kuptsova-Clarkson N; Liu S; Patel P; Rotolo F; Mitry E; Pastan I; Giles F;
J Hematol Oncol; 2021 Feb; 14(1):35. PubMed ID: 33627164
[TBL] [Abstract][Full Text] [Related]
13. Development of Recombinant Immunotoxins for Hairy Cell Leukemia.
Kreitman RJ; Pastan I
Biomolecules; 2020 Aug; 10(8):. PubMed ID: 32756468
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of Immunotoxins Containing
Mazor R; Pastan I
Front Immunol; 2020; 11():1261. PubMed ID: 32695104
[TBL] [Abstract][Full Text] [Related]
15. A high-throughput lysosome trafficking assay guides ligand selection and elucidates differences in CD22-targeted nanodelivery.
Vaughan HJ; Est-Witte S; Dockery LT; Urello MA; Boyd J; Keyser BD; Zhuang L; Marelli M; Christie RJ
Sci Technol Adv Mater; 2024; 25(1):2351791. PubMed ID: 38817250
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic proteins: developments, progress, challenges, and future perspectives.
Kumar V; Barwal A; Sharma N; Mir DS; Kumar P; Kumar V
3 Biotech; 2024 Apr; 14(4):112. PubMed ID: 38510462
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Antibodies in Medicine.
Sharma P; Joshi RV; Pritchard R; Xu K; Eicher MA
Molecules; 2023 Sep; 28(18):. PubMed ID: 37764213
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
